China Medicine Corp.

As of September 30, 2010, China Medicine Corp. carries a market capitalization of 48.85M, placing it among publicly traded companies globally. Its enterprise value stands at 44.48M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of September 30, 2010, China Medicine Corp. has 23.71M shares outstanding.

As of September 30, 2010, China Medicine Corp. trades at a trailing price-to-earnings ratio of 8.16. The price-to-sales ratio is 0.75, and the price-to-book ratio stands at 0.63.

As of September 30, 2010, China Medicine Corp. trades at an EV/EBITDA multiple of 3.32 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.68 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 3.80 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. China Medicine Corp. trades at an EV/FCF ratio of 6.92, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 44.48M versus a market cap of 48.85M, with the gap driven by net debt and cash on the balance sheet.

As of September 30, 2010, China Medicine Corp. maintains a current ratio of 11.15, meaning it holds 11.2x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended September 30, 2010, China Medicine Corp. posted a return on equity (ROE) of 9.72, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 10.60 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.45, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 9.67, useful for judging operating efficiency across full business cycles. The company generates approximately 233,999.88 in revenue per employee across its workforce of 281.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 6.33 indicates how many times China Medicine Corp. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended September 30, 2010, China Medicine Corp. recorded 3.76M in income tax expense. That works out to an effective tax rate of 39.67, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 9.48M, leaving 6.03M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, China Medicine Corp.'s stock has declined approximately 16.36% over the past 52 weeks. The 50-day moving average sits at 0.03, while the 200-day moving average is 0.03.

Over the twelve months ended September 30, 2010, China Medicine Corp. generated 65.75M in revenue and converted that into 6.03M in net income, yielding earnings per share of 0.20. EBITDA reached 13.41M, while operating income came in at 11.70M.

As of September 30, 2010, China Medicine Corp. holds 7.85M in cash and equivalents against 3.20M in total debt, resulting in a net debt position of -4.65M. Total book value stands at 77.63M, with working capital of 85.75M providing operational flexibility.

China Medicine Corp. produced 11.01M in operating cash flow over the twelve months ended September 30, 2010. After subtracting -4.58M in capital expenditures, free cash flow totaled 6.43M - equivalent to 0.27 per share.

Over the twelve months ended September 30, 2010, China Medicine Corp. posted a gross margin of 33.46, reflecting its pricing power and cost economics. The operating margin of 17.80 and net profit margin of 9.17 provide insight into operational efficiency.

These figures cover the twelve months ended September 30, 2010. Free cash flow yield stands at 10.96, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -9.74, meaning China Medicine Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of September 30, 2010, China Medicine Corp. has an Altman Z-Score of 2.58, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.